Correlation of a quinidine-induced platelet-specific antibody with development of thrombocytopenia.
The rapidity by which drug-dependent antiplatelet antibodies can develop is not known, since patients are only studied during or after the episode of thrombocytopenia. This report describes the development of quinidine-induced immune thrombocytopenia in a healthy volunteer during a drug study. The thrombocytopenia developed within two weeks of initiation of quinidine therapy. During the thrombocytopenic episode, but not before receiving the drug, the patient had an IgG antiplatelet antibody that bound to control platelets in the absence of the drug. This antibody was absent when the drug was discontinued and the platelet count rose. The patient's acute serum also induced the release of serotonin from control platelets, and the reaction was enhanced by quinidine. This indicates that drug-dependent antiplatelet antibodies can develop rapidly and supports the hypothesis that quinidine-induced thrombocytopenia is due to a quinidine-dependent platelet-specific IgG.
D000328:Adult; D000917:Antibody Formation / Q000187:drug effects*; D001323:Autoantibodies / Q000276:immunology*; D001792:Blood Platelets / Q000276:immunology; D005260:Female; D006801:Humans; D011802:Quinidine / Q000009:adverse effects*; D012701:Serotonin / Q000378:metabolism; D013921:Thrombocytopenia / Q000139:chemically induced / Q000276:immunology*
D001323:Autoantibodies; D012701:Serotonin; D011802:Quinidine